INFORMATION DISCLOSURE CITATION

Atty. Docket No.:	03804.1129-00000		
Applicant:	Jean-Francois DEDIEU et al.	**Serial No.:**	Unassigned
Filing Date:	August 31, 2000	**Group Art Unit:**	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date	Name	Class	Sub Class	Filing Date (if appropriate)
	1	4,939,088	07/1990	Young et al.	435	320.1	
	2	5,194,601	03/1993	Sugden et al.	435	320.1	
	3	5,672,344	09/30/97	Kelley et al.	424	172.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
	4	WO 92/05262	4/1992	WIPO			
	5	WO 93/19191	3/1993	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	6	**Clayman et al.,** *"Adeno p53 Gene Transfer in a Phase I/II Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma,"* Soc. for Biol. Therapy, Ann. Meeting, Abstract (1996)
	7	**Clayman et al.,** *"Adenovirus Mediated p53 Gene Transfer in a Phase I Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma,"* ASCO Annual Meeting, Abstract (1997)
	8	**Clayman et al.,** *"Adenovirus Mediated p53 Gene Transfer in Patient with Advanced Recurrent Head and Neck Squamous Carcinoma,"* AACR Annual Meeting, Abstract
	9	**Clayman et al.,** *"Gene Therapy for Head and Neck Cancer: Comparing the Tumor Suppressor Gene p53 and a Cell Cycle Regulator WAFI/CIP1 (p21),"* Arch. Otolaryngol. Head Neck Surgery, Vol. 122, pp. 489-493 (1996)

Examiner:	Dalbo	**Date Considered:**	5/17/02

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	10	**Coghlan**, *"New Scientist,"* Vol. 149, pp. 14-15 (1995)
	11	**Crystal,** *"Transfer of genes to humans: early lessons and obstacles to success,"* Science Vol. 270, pp. 404-409 (1995)
	12	**Dong et al.,** *"Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus,"* Human Gene Therapy Vol. 7, pp. 319-331 (1996)
	13	**Karlsson,** *"Treatment of genetic defects in hematopoietic cell function by gene transfer,"* Blood, Vol. 78, No. 10, pp. 2481-2492 (1991)
	14	**Kozarsky et al.,** *"Gene therapy: adenovirus vectors,"* Current Opinion on Genetics and Development, Vol. 3, pp. 499-503 (1996)
	15	**Marshall**, *"Gene therapy's growing pains,"* Science, Vol. 269, pp. 1050-1055 (1995)
	16	**Marshall**, *"Less hype, more biology needed for gene therapy,"* Science, Vol. 270, p. 1751 (1995)
	17	**Marx,** *"Cell death studies yield cancer clues,"* Science, Vol. 259, pp. 760-761 (1996)
	18	**Mastrangeli et al.,** *"Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer,"* The Journal of Clinical Investigation, Vol. 91, pp. 225-234 (1993)
	19	**Morsy et al.,** *"Progress toward human gene therapy,"* JAMA, Vol. 270, No. 19, pp. 2338-2345 (1993)
	20	**Orkin & Moltulsky**, NIH Report on Gene Therapy, (Dec. 7, 1995)
	21	**Perricaudet et al.**, Ann. Oncol., Vol. 3, Suppl. 5, p. 135 (1992)
	22	**Roth et al.,** *"Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer,"* Nature Medicine, Vol. 2, pp. 985-991 (1996)
	23	**Sugden et al.,** *"A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection,"* Journal of Virology, pp. 2644-2649 (1989)
	24	**Swisher et al.,** *"Persistant Transgene Expression Following Repeated Injections of a Recombinant Adenovirus Containing the p53 Wild-Type Gene in Patients with Non-Small Cell Lung Cancer,"* AACR Annual Meeting, Abstract
	25	**Swisher et al.,** *"Adenoviral Mediated p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC),"* ASCO Annual Meeting, Abstract (1997)
	26	**Zimber-Strobl et al.,** *"Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene,"* Journal of Virology pp. 415-423 (1991)

Examiner: Dash	**Date Considered:** 5/17/02
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-1449	Patent and Trademark Office - U.S. Department of Commerce